Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Donald Trump charged with 37 counts in classified documents case
    • Erdoğan taps former Goldman Sachs banker to head Turkey’s central bank
    • Ukraine sends western tanks into battle as counter-offensive gets under way
    • Donald Trump says he has been indicted on federal charges in documents probe
    • Canadian wildfire smoke jars New York with ‘movie of the future’
  • UK
    Sections
    • UK Home
    • UK Business & Economy
    • UK Politics & Policy
    • Brexit
    • UK Companies
    • Personal Finance
    Most Read
    • Johnson quits parliament in protest at MPs’ ‘kangaroo court’
    • How stubborn inflation has undermined the UK housing market
    • Boris Johnson calls time on parliament ‘for now’ — and that spells trouble for Sunak
    • Apache announces end to North Sea drilling hours after UK scales back windfall tax
    • Crypto ownership doubles in UK before new rules kick in
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Goldman, Exane and Schroders cut ties with Odey Asset Management after assault claims
    • Financier who used fraud proceeds to fund ‘lavish lifestyle’ sentenced to 14 years
    • How the Barclays lost The Telegraph
    • Anne Boden stepped down as Starling CEO after investor clash
    • FCA investigates Odey Asset Management
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    Most Read
    • Live news updates from June 9: Trump charged with 37 counts, Boris Johnson to stand down from parliament
    • Goldman, Exane and Schroders cut ties with Odey Asset Management after assault claims
    • Binance US to suspend dollar transactions after payment partners pause activity
    • Norway seeks to open vast ocean area to deep-sea mining
    • FCA investigates Odey Asset Management
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • Lex
    • Obituaries
    • Letters
    Most Read
    • Apple’s Vision Pro headset has made the metaverse feel outdated
    • Trump indictment brings him closer to the danger zone
    • How US cities became one big parking lot
    • Luxury goods: Europe’s joke on the world
    • Ukraine’s dam explosion is a red line: Russia must feel the consequences
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • Too good to be true? The fake recruiters targeting jobseekers
    • Can a virtual PA turbocharge your career?
    • Anti-monarchist Graham Smith: The British royals are ‘tax-funded Kardashians’
    • FT business books: what to read this month
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • François Hollande: ‘Putin cannot be seduced. He respects force’
    • How Crispin Odey evaded sexual assault allegations for decades
    • Don’t blame us for AI’s threat to humanity, we’re just the technologists
    • An Albanian adventure
    • Buying into Comporta, bohemian enclave turned luxury hotspot
  • HTSI
MenuSearch
  • Home
  • World
  • UK
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
SubscribeSign In

Dementia

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Friday, 9 June, 2023
    Camilla Cavendish
    An ageing society can’t turn its back on social care any longer

    Governments have promised to tackle the crisis for 25 years, but it’s never an election winner

  • Sunday, 14 May, 2023
    Japan pushes for strong pledges on tackling dementia from G7 allies

    Alzheimer’s advocates call for ambitious declaration to match the scope of commitments made 10 years ago

  • Monday, 8 May, 2023
    Two Alzheimer’s drugs offer hope to patients after decades of waiting

    In clinical trials, the medications slowed the progress of the degenerative disease that affects 50mn worldwide

  • Wednesday, 3 May, 2023
    Eli Lilly & Co
    Eli Lilly to seek US approval after Alzheimer’s drug trial success

    Clinical study results could boost patient access to new class of treatment

  • Wednesday, 19 April, 2023
    ReviewFT Books Essay
    Alternative realities: caring for people with dementia

    With an ageing global population, cases of the disease continue to drastically rise. Two timely and insightful books offer help on how to support the millions of new patients

  • Monday, 20 February, 2023
    OutlookPatti Waldmeir
    How banks may catch signs of dementia before the doctors do

    Money problems experienced by elderly customers can be red flags for families and institutions alike

  • Wednesday, 11 January, 2023
    Anjana Ahuja
    New Alzheimer’s drug straddles uneasy gulf between help and harm

    For all its landmark status, lecanemab may end up representing a triumph of hope over evidence

  • Thursday, 29 December, 2022
    Biogen Inc
    Congress faults US regulator’s approval of Biogen Alzheimer’s drug

    Committees cite inappropriate collaboration between FDA and drugmaker

  • Friday, 2 December, 2022
    Pharmaceuticals sector
    Swedish scientist behind Alzheimer’s drug has big ambitions

    Lars Lannfelt had a key role in developing a drug that has shown some promise in tackling Alzheimer’s

  • Friday, 2 December, 2022
    The editorial board
    A glimmer of hope in treating Alzheimer’s disease

    Dementia drug development, diagnostics and delivery still require much more investment

  • Wednesday, 30 November, 2022
    Eisai says Alzheimer’s drug did not cause deaths of trial patients

    Japanese company refuses to rule out possibility treatment contributed to brain bleeds

  • Tuesday, 29 November, 2022
    Eisai Co Ltd
    Japan’s Eisai aims to silence critics over breakthrough Alzheimer’s drug

    Shares fall 11% following two patient deaths in trials of lecanemab

  • Monday, 28 November, 2022
    LexDrugs research
    Dementia/Biogen: causal controversy means investors must take a stance Premium content

    The early death of an Alzheimer’s patient taking part in lecanemab trials sent shares down

  • Monday, 14 November, 2022
    Roche Holding AG
    Roche late-stage Alzheimer’s trials end in failure

    Two studies of antibody treatment gantenerumab fail to slow decline in people with early-stage disease

  • Sunday, 13 November, 2022
    Insurance
    AI is giving insurers godlike powers, says Sompo chief

    Access to large data sets means predictions are far more accurate in reducing risk

  • Monday, 24 October, 2022
    Special ReportFT Health: Communicable Diseases
    Evidence builds of viruses’ role in Alzheimer’s disease

    Researchers focus on pathogens including Covid, herpes and Epstein-Barr virus

  • Wednesday, 28 September, 2022
    Pharmaceuticals sector
    Biogen and Eisai shares surge after Alzheimer’s drug trial success

    Pharma groups seek US regulatory approval as clinical trial shows monoclonal antibody treatment slowed disease

  • Friday, 23 September, 2022
    Health sector
    Alzheimer’s drug trial brings pivotal test of maligned brain plaque theory

    Study of Eisai treatment will be one of last chances to prove amyloid hypothesis, say experts

  • Monday, 22 August, 2022
    Medical science
    Electrical brain stimulation improves memory in elderly, research finds

    Study could be used to help boost cognitive performance of people developing Alzheimer’s disease

  • Wednesday, 17 August, 2022
    Coronavirus
    Covid can cause brain disorders two years after infection, study shows

    Long-term effects are generally less in children, although infection doubles risk of epilepsy

  • Wednesday, 18 May, 2022
    Coronavirus
    How can Covid-19 affect the human brain?

    Scientists are trying to understand the cause of neurological effects and whether symptoms will be long-lasting

  • Sunday, 17 April, 2022
    Anjana Ahuja
    Hasty approval for Alzheimer’s drug offers a cautionary tale

    FDA’s green light for aducanumab may delay development of more effective treatments for dementia, critics say

  • Friday, 8 April, 2022
    News in-depthPharmaceuticals sector
    US imposes strict curbs on contentious Biogen Alzheimer’s treatment

    Agency that controls spending by government health schemes will not fund drug for most patients

  • Thursday, 13 January, 2022
    ReviewNon-Fiction
    What I Wish People Knew About Dementia — uplifting depiction

    Practical and reassuring tale written with eloquence and insight about a disease which for years was presumed to rob sufferers of sentience

  • Wednesday, 20 October, 2021
    Biogen Inc
    Biogen sells just $300,000 worth of contentious Alzheimer’s drug

    Third-quarter revenues from $56,000-per-year treatment were well below analysts’ expectation of $10m

Previous page You are on page 1 Next page

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsFT Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

UK Edition

Subscribe for full access
  • Switch to International Edition

Top sections

  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
  • UK
    • UK Business & Economy
    • UK Politics & Policy
    • Brexit
    • UK Companies
    • Personal Finance
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • HTSI
  • Special Reports

FT recommends

  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Live Events
  • FT Forums
  • Board Director Programme
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In